公开(公告)号：US20220389037A1

公开(公告)日：2022-12-08

申请号：US17624514

申请日：2020-07-03

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Xiaotian Zhu ,  Song Feng ,  Lei Wu ,  Wei Huang ,  Hao Liu ,  Rongqiang Liu ,  Kate Xin Wen ,  Hua Zhou

IPC: C07F9/6561 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D519/00 ,  C07D491/107 ,  C07D487/04 ,  C07D473/32 ,  C07F9/6558 ,  C07D498/04 ,  A61K45/06

Abstract: Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.

公开(公告)号：US20230339896A1

公开(公告)日：2023-10-26

申请号：US18013402

申请日：2021-07-02

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Xiaotian Zhu ,  Song Feng ,  Lei Wu ,  Wei Huang ,  Hao Liu ,  Rongqiang Liu ,  Kate Xin Wen ,  Hua Zhou

IPC: A61P35/00 ,  C07D401/14

CPC classification number: C07D401/14 ,  A61P35/00

Abstract: The invention provides a compound represented by structural formula (I) or formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPKl activity.